Sign up
Quantellect · Analysts · Analyst Profile
Q Score Rank#9 of 388

Mayank Mamtani

B. Riley Securities · Equity Research Analyst
✓ SkilledProvisionalRating since 2020No new ratings since Jul 2025

Analyst rating accuracy & track record

Mayank Mamtani is an equity research analyst at B. Riley Securities. Quantellect has scored 27 of their stock calls across 20 companies. Their picks beat their sector 53% of the time over the next 12 months, and their price targets were reached 38% of the time within a year.

Win % vs sector
53%
PT Hit % (12mo)
38%
Avg sector-excess
+10.6%
Scored calls
27
Tickers
20
Tier
Provisional
Skilled

Track record

Quantellect has scored 27 of Mayank Mamtani's stock calls across 20 companies, dating back to 2020. Their rated stocks beat their own sector 53% of the time over the next 12 months. On a typical call, a Mamtani pick returned +10.6% more than its sector over the following year.

Of the scored calls, 27 were bullish (Buy). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
NKTRNektar Therapeutics
Buy$85.00Jul 2025+186.4%Hit
AGENAgenus Inc
Buy$8.00Jul 2025−57.5%Miss
MNOVMediciNova Inc
Buy$5.00Jun 2025−12.2%Miss
MDGLMadrigal Pharmaceuticals Inc
Buy$460.00May 2025+62.6%Hit
TRVITrevi Therapeutics Inc
Buy$20.00Mar 2025+60.4%Miss
DNLIDenali Therapeutics Inc
Buy$35.00Mar 2025+16.2%Miss
ARWRArrowhead Pharmaceuticals Inc
Buy$38.00Feb 2025+200.8%Hit
VKTXViking Therapeutics Inc
Buy$96.00Feb 2025−11.6%Miss
NKTRNektar Therapeutics
Buy$4.00Jan 2025+153.0%Hit
NVAXNovavax Inc
Buy$26.00Oct 2024−27.5%Miss
CNTACentessa Pharmaceuticals PLC ADR
Buy$33.00Sep 2024+19.2%Miss
ALTAltimmune Inc
Buy$20.00Aug 2024−30.9%Miss
TGTXTG Therapeutics Inc
Buy$34.00Aug 2024+51.3%Hit
ALTAltimmune Inc
Buy$20.00Jun 2024+30.1%Miss
TGTXTG Therapeutics Inc
Buy$29.00Feb 2024+110.7%Hit
TGTXTG Therapeutics Inc
Buy$24.00Oct 2023+243.5%Hit
SCLXScilex Holding Company
Buy$4.00Oct 2023−77.1%Miss
XFORX4 Pharmaceuticals Inc
Buy$3.00Apr 2023+24.9%Miss
FBIOFortress Biotech Inc
Buy$6.00Jul 2022−43.0%Miss
XFORX4 Pharmaceuticals Inc
Buy$7.00May 2022+78.2%Miss
MBIOMustang Bio Inc
Buy$6.00Jan 2022−48.7%Miss
INMBINmune Bio Inc
Buy$20.00Jan 2022−22.4%Miss
BIVIBiovie Inc
Buy$27.00Nov 2021+5.1%Miss
FWONKLiberty Media Corporation Series C Liberty Formula One Common Stock
Buy$39.00Mar 2020+14.8%Hit
FBIOFortress Biotech Inc
Buy$6.00Mar 2020+231.8%Miss
GLMDGalmed Pharmaceuticals Ltd
Buy$11.00Mar 2020−41.4%Miss
MNOVMediciNova Inc
Buy$11.00Mar 2020+22.3%Hit
Go to

Mayank Mamtani: analyst track record FAQ

Is Mayank Mamtani a good stock analyst?

Yes, by track record. Mayank Mamtani ranks number 9 of 388 of the analysts Quantellect scores, with a Q Score of 82 out of 100. Their edge holds up after we account for testing thousands of analysts at once, so they clear our Skilled bar. Past results do not guarantee future ones.

What is Mayank Mamtani's win rate?

Mayank Mamtani's win rate is 53%. Across 27 scored calls, their rated stocks beat their sector 53% of the time over the next 12 months. On a typical call they returned +10.6% more than the sector.

What stocks and sectors does Mayank Mamtani cover?

Mayank Mamtani covers 20 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.

Are Mayank Mamtani's price targets accurate?

Mayank Mamtani's price targets are reached within 12 months 38% of the time. The base rate across all analysts Quantellect tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Quantellect scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Mayank Mamtani's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Quantellect score analyst accuracy?

Quantellect scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Mayank Mamtani rank among Wall Street analysts?

Mayank Mamtani ranks number 9 of 388 by Q Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Quantellect calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.